Alzheimer's Drug Discovery Foundation logo

Alzheimer's Drug Discovery Foundation

Public charity · Grantmaker New York, NY EIN: 20-1082179 Website

The Alzheimer's Drug Discovery Foundation (ADDF) is a New York, New York-based public charity focused on accelerating the development of drugs to prevent, treat, and cure Alzheimer’s disease. Founded in 1998, it supports research in academia and the biotech industry through a venture philanthropy model.

Alzheimer's Drug Discovery Foundation at a glance

In short: Alzheimer's Drug Discovery Foundation gave $54.8M across 26 grants in 2024 (avg $2.1M), top state California. 65% of 2024 grantees were new. Source: 2024 IRS Form 990.

Annual giving (2024)
$54,800,524
+53.6% vs 2023
Grants made (2024)
26
+0.0% vs 2023
Average grant
$2,107,712
+53.6% vs 2023
Median grant
$694,460
Total assets
$299,394,693
-7.6% vs 2023
New grantees (estimate)
65% first-time grantees (17 of 26, 2024)
Primary geography
California (38% of itemized 2024 grant dollars)
Latest 990 filing
Form 990, 2024 View filing

Data from IRS Form 990, 2024; updated October 2026. New grantees are estimated by matching recipient names across years (methodology).

How to apply to Alzheimer's Drug Discovery Foundation

Accepts unsolicited proposals
No
Review Cycle
The website lists December 7, 2026, for invited full proposals under the Drug Development and Neuroimaging and CSF Biomarker RFPs; the LOI date has passed. It also lists the ADDF-Harrington Scholar Program RFP’s LOI and full-proposal dates as passed.
Deadline
The website lists December 7, 2026, for invited full proposals under the Drug Development and Neuroimaging and CSF…
Contact

Mailing address: 57 West 57Th St 904, New York, NY 10019
Phone: (212) 901-8000
Website: https://alzdiscovery.org

Application details from Grantable's research on the foundation's public materials; confirm on its website before applying.

Who Alzheimer's Drug Discovery Foundation funds

How this funder distributes its grants

Top Recipients

Top 10 recipients in 2024

Alamar Biosciences: $10.0MAlamar Biosciences$10.0MC2N Diagnostics: $7.0MC2N Diagnostics$7.0MPharmatrophix: $5.6MPharmatrophix$5.6MCoya Therapeutics: $5.0MCoya Therapeutics$5.0MMetro International Biotechedenroc: $5.0MMetro InternationalBiotechedenroc$5.0MModulo Bio Inc: $4.8MModulo Bio Inc$4.8MUniversity of Nevada Las Vegas: $3.2MUniversity of Nevada Las Vegas$3.2MAquinnah Pharmaceuticals: $3.0MAquinnah Pharmaceuticals$3.0MDavos Alzheimers Collaborative: $2.5MDavos Alzheimers Collaborative$2.5MUniversity of Arizona - Health Sciences: $1.8MUniversity of Arizona - HealthSciences$1.8M

The largest 2024 recipient was Alamar Biosciences ($10.0M). Together the top 10 received $48.0M.

Grant Size Distribution

128 grants across all recorded years

14<$50K6$50–100K16$100–250K17$250–500K30$500K–1M37$1–5M8$5M+

The most common grant size was in the $1–5M range: 37 grants of 128 (29%).

Geographic Focus

Where this funder awards grants

ADDF says it funds academic centers and biotechnology companies around the world. In 2024, the largest shares of reported grant dollars went to recipients in California (38%), Massachusetts (16%), Missouri (13%), Texas (11%), and New York (6%).

Grant Distribution by State

24states

Share of 2024 grant dollars across all 26 itemized grants.

Cities

BostonNew YorkCambridgeWashingtonSan DiegoSan FranciscoAmesBethesdaBrooklineSacramentoBaltimoreClevelandRochesterSan FransicoSt. LouisArlingtonAtlantaBerkeleyCantonLas Vegas

Is Alzheimer's Drug Discovery Foundation open to new grantees?

65%

first-time grantees, 2024

In 2024, 17 of 26 grantees (65%) were first-time recipients. First grants averaged $2.2M; repeat grants $1.9M. How we count

Medians: $789K first-time, $494K repeat.

  • 19% of 2024 grantees were also funded in 2023. Method
  • Giving grew 56% from 2021 to 2024. Method

Estimate from itemized grant lists in IRS Form 990 filings (2019–2024). Recipient names are matched across years, so a renamed or misspelled grantee can look new; grants to individuals are left out. Methodology.

Giving History

Giving Over Time

Total grant dollars and number of grants per year

$0$20M$40M$60M18 grants2019 24 grants2020 34 grants2021 18 grants2022 26 grants2023 26 grants2024

From 2019 to 2024, annual grant giving ranged from $16.8M (2020) to $54.8M (2024). In 2024 it made 26 grants totaling $54.8M.

Grants by year

Grant recipients and amounts by year

RecipientPurposeAmount
Alamar Biosciences Fremont, CAAlzheimers Research$10,016,094
C2N Diagnostics St. Louis, MOAlzheimers Research$7,025,121
Pharmatrophix Menlo Park, CAAlzheimers Research$5,609,700
Coya Therapeutics Houston, TXAlzheimers Research$5,000,000
Metro International Biotechedenroc Cambridge, MAAlzheimers Research$5,000,000
Modulo Bio Inc San Diego, CAAlzheimers Research$4,845,794
University of Nevada Las Vegas Las Vegas, NVAlzheimers Research$3,247,762
Aquinnah Pharmaceuticals Cambridge, MAAlzheimers Research$2,999,586
Davos Alzheimers Collaborative Philadelphia, PAAlzheimers Research$2,500,000
University of Arizona - Health Sciences Tucson, AZAlzheimers Research$1,774,201
Your AI grants department

Ready to take the next step with Alzheimer's Drug Discovery Foundation?

Fully replaces Grant database subscriptions Instrumentl · Foundation Directory · GrantStation & similar

Financial History

Multi-year comparison from IRS filings

Figures from IRS filings, by filing year
Filing yearTotal AssetsRevenueExpensesGrants paidGrantsNet Investment Income
2024$299,394,693$47,282,987$88,250,427$54,800,52426$5,534,433
2023$324,173,528$37,742,020$61,943,588$35,675,28826$3,119,933
2022$340,253,841$254,027,105$36,842,901$21,272,54018$-2,054,312
2021$116,420,075$53,037,104$37,126,176$35,117,76734$206,491
2020$97,381,722$27,631,350$28,251,909$16,790,22024$1,230,614
2019$97,175,562$22,712,391$32,429,304$17,292,04118$948,041

Research compiled by Grantable AI from public sources. Last updated October 2026.

Mission & Focus Areas

ADDF’s stated mission is to accelerate the discovery of drugs to prevent, treat, and cure Alzheimer’s disease and related dementias. Its website describes funding for therapeutic and biomarker development, including early-stage drug studies and clinical trials, biomarker development and validation, and studies of whether drugs affect dementia risk or cognitive decline. Its Drug Development RFP includes novel, repurposed, and repositioned drugs, as well as devices, for Alzheimer’s disease and related dementias.

ADDF supports academic and nonprofit institutions and biotechnology companies. Examples among its 2024 recipients include Johns Hopkins University, whose stated work spans education and research across disciplines, and USAgainstAlzheimer’s, which describes work on prevention, early detection and diagnosis, and access to treatments. The Global Alzheimer’s Platform Foundation describes its work as coordinating with international partners on clinical-trial innovation.

Grantmaking

In filing year 2024, ADDF reported 26 grants totaling $54,800,524. The grants ranged from $9,992 to $10,016,094, with a median of $694,460. The largest reported awards included $10,016,094 to Alamar Biosciences, $7,025,121 to C2N Diagnostics, $5,609,700 to Pharmatrophix, and $5,000,000 each to Coya Therapeutics and Metro International BiotechedEnroc. The filing listed the purpose of these awards as Alzheimer’s research.

ADDF’s website describes a two-step application process: applicants submit a letter of intent (LOI), and invited applicants submit a full proposal. LOIs are assessed for fit with ADDF’s mission and priorities; invited full proposals undergo external scientific and business review and further due diligence. The LOI requests project details, scientific rationale, specific aims or milestones, and supporting data. Biotechnology companies may submit one LOI and one invited full proposal per cycle; academic institutions may have multiple applicants for different projects. For therapeutic RFPs, applicants may resubmit up to twice if they address reviewer concerns. Under the policy effective in 2026, a full proposal must be submitted in the same cycle as its LOI. ADDF’s website says the current round of its Peripheral Biomarkers and Digital Biomarkers RFPs is closed and that it is no longer accepting unsolicited applications for those programs.

Leadership & Key People

Leadership team and compensation from IRS filings

The 2024 filing lists Howard Fillit as founding executive director and chief science officer. It also lists Adam Hoffman, Alice Shure, Ann Jackson, Bonnie Englebardt Lautenberg, Bonnie Pfeifer Evans, Carol Boulanger, David Weinreb, Gary M. Lauder, and Henrik Zetterberg as governors.

Alzheimer's Drug Discovery Foundation is led by Mark Roithmayr, CEO on every filing since 2019; 8 of 37 officers listed in 2024 are compensated.

Officers on the 2024 filing

  • Mark Roithmayr

    CEO

    On filings since 2019

    40 hrs/week

    $153K (2020) → $651K (2024)

  • Howard Fillit MD

    Founding Executive Director & Chief Science Officer

    Founding Executive Director & Chief Science Officer → Founding Executive Director & Chief Sci. Officer, 2023

    Founding Executive Director & Chief Sci. Officer → Founding Executive Director & Chief Science Officer, 2024

    On filings since 2019

    40 hrs/week

    $426K (2019) → $663K (2024)

  • Laura Nisenbaum

    Executive Director & Drug Development

    On filings since 2022

    40 hrs/week

    $430K (2022) → $443K (2024)

  • Leonard A. Lauder

    Co-Chairman & Governor

    Co-Chair & Governor → Co-Chairman & Governor, 2022

    On filings since 2019

    1 hr/week

    No compensation reported

  • Ronald S. Lauder

    Co-Chairman & Governor

    Co-Chair & Governor → Co-Chairman & Governor, 2022

    On filings since 2019

    1 hr/week

    No compensation reported

  • Eli Shobin

    Senior Director Dxa

    New on the 2024 filing

    40 hrs/week

    $236K (2024)

  • Karen Harris

    CFO & Head of Mission Related Investment

    CFO & Head of Mission Relate → CFO & Head of Mission, 2023

    CFO & Head of Mission → CFO & Head of Mission Related Investment, 2024

    On filings since 2021

    40 hrs/week

    $110K (2021) → $369K (2024)

  • Jane McIntosh

    Chief External Affairs

    Chief External Affairs & Philanthropy Officer → Chief External Affairs, 2023

    On filings since 2022

    40 hrs/week

    $310K (2022) → $378K (2024)

  • Aaron Burstein

    Head of Search & Evaluation

    On filings since 2023

    40 hrs/week

    $302K (2023) → $314K (2024)

  • Lakita Cavin

    Attorney & Mission-Related

    Attorney & Mission-Related Investments → Attorney & Mission-Related, 2024

    On filings since 2023

    40 hrs/week

    $208K (2023) → $220K (2024)

  • Alice Shure

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Bonnie Pfeifer Evans

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Gary M. Lauder

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Lanny Edelsohn MD

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • LAURENCE C LEEDS Jr.

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Nancy Corzine

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Nancy Goodes

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Paula Zahn

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Randal Sandler

    Co-Vice Chairman & Secretary

    Vice Chair & Governor → Co-Vice Chairman, Secretary & Governor, 2022

    Co-Vice Chairman, Secretary & Governor → Co-Vice Chairman & Secretary, 2023

    On filings since 2019

    1 hr/week

    No compensation reported

  • Richard Mohs PhD

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Roberta Diaz Brinton PhD

    Governor

    On filings since 2019

    1 hr/week

    No compensation reported

  • Thomas F. McWilliams

    Co-Vice Chairman & Treasurer

    Governor → Co-Vice Chairman, Treasurer & Governor, 2022

    Co-Vice Chairman, Treasurer & Governor → Co-Vice Chairman & Treasurer, 2023

    On filings since 2019

    1 hr/week

    No compensation reported

  • David Weinreb

    Governor

    On filings since 2020

    1 hr/week

    No compensation reported

  • Sharon Sager

    Governor

    On filings since 2020

    1 hr/week

    No compensation reported

  • Miia Kivipelto MD PhD

    Governor

    On filings since 2021

    1 hr/week

    No compensation reported

  • Thomas Smith Jr.

    Governor

    On filings since 2021

    1 hr/week

    No compensation reported

  • Adam Hoffman

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Ann Jackson

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Bonnie Englebardt Lautenberg

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Carol Boulanger

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Henrik Zetterberg MD PhD

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Julieann Shanahan CFA

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Laura Steele

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Niranjan Bose PhD

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Philip Scheltens MD PhD

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Rachid Izzar

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

  • Ric Edelman

    Governor

    New on the 2024 filing

    1 hr/week

    No compensation reported

Former officers (21)
  • Former: Robert A. Belfer (2019–2023) — Governor
  • Former: Sandra Day O'Connor (2020–2023) — Honorary Chairman
  • Former: Beatriz Illescas Putzeys-Claugus (2022–2023) — Governor
  • Former: Melvin Goodes (2022–2023) — Honorary Governor
  • Former: Christopher Carlson (2023) — Director, Search & Evaluation
  • Former: Sally Susman (2021–2022) — Honorary Governor
  • Former: Jennifer S. Iselin (2022) — Director & Special Events
  • Former: Marina D'emic (2022) — Director of Finance
  • Former: Sarah Giardina (2022) — Associate Director & Dxa
  • Former: Beatriz Iiiescas (2020–2021) — Governor
  • Former: Mel Goodes (2020–2021) — Governor
  • Former: Shobha Prushothama (2020–2021) — Scientist
  • Former: Giorgio Zeolla (2021) — Director
  • Former: Janie Shissler (2021) — Scientist
  • Former: Mark Forman (2021) — Scientist
  • Former: BRUCE McEWEN PhD (2019–2020) — Governor
  • Former: Kevin Dieterich (2019–2020) — Treasurer
  • Former: Lisa Somar (2019–2020) — Assistant Treasurer & Secretary
  • Former: Lauren Friedman (2020) — Scientist
  • Former: Yuko Hara (2020) — Scientist
  • Former: Steven Marc Paul MD (2019) — Governor

Data from IRS Form 990 filings, 2019–2024. "On filings since" is the earliest filing we hold that lists the person; hours are average hours per week as reported.

Compensation Overview

From 2024 IRS filing

Howard Fillit MD — Founding Exec. DIR. & Chief Science Off.: $663KHoward Fillit MDFounding Exec. DIR. & Chief…$663KMark Roithmayr — CEO: $651KMark RoithmayrCEO$651KLaura Nisenbaum — Executive Director, Drug Development: $443KLaura NisenbaumExecutive Director, Drug…$443KJane McIntosh — Chief External Affairs: $378KJane McIntoshChief External Affairs$378KKaren Harris — CFO and Head of Mission Related INV: $369KKaren HarrisCFO and Head of Mission Related…$369KAaron Burstein — Head of Search and Evaluation: $314KAaron BursteinHead of Search and Evaluation$314KEli Shobin — Senior Director DXA: $236KEli ShobinSenior Director DXA$236KLakita Cavin — Attorney, Mission-Related: $220KLakita CavinAttorney, Mission-Related$220K

The highest reported compensation on the 2024 filing was $663K, to Howard Fillit MD (Founding Exec. DIR. & Chief Science Off.). 8 officers or directors reported compensation on that filing.

Frequently asked questions about Alzheimer's Drug Discovery Foundation

How much does Alzheimer's Drug Discovery Foundation give each year?

Alzheimer's Drug Discovery Foundation gave $54.8M across 26 grants in 2024, according to its 2024 IRS Form 990. In 2023 it gave $35.7M across 26 grants.

What is Alzheimer's Drug Discovery Foundation's typical grant size?

Alzheimer's Drug Discovery Foundation's median grant in 2024 was $694,460, and its average grant was $2,107,712, across 26 grants on its 2024 IRS Form 990. Organizations receiving their first grant from Alzheimer's Drug Discovery Foundation that year got $2.2M on average.

Where does Alzheimer's Drug Discovery Foundation give grants?

Alzheimer's Drug Discovery Foundation's top state is California, with 38% of the grant dollars itemized on its 2024 IRS Form 990. The next largest states were Massachusetts (16%) and Missouri (13%). The most frequent recipient cities were New York, NY (3 grants), Cambridge, MA (2 grants) and Washington, DC (2 grants).

Does Alzheimer's Drug Discovery Foundation give general operating support?

Not in 2024: none of the 26 grants with a stated purpose on Alzheimer's Drug Discovery Foundation's 2024 IRS Form 990 were described as general or operating support. Recurring purposes include "Alzheimers Research" (26 grants).

Who are Alzheimer's Drug Discovery Foundation's largest grantees?

Alzheimer's Drug Discovery Foundation's largest 2024 grantees include Alamar Biosciences ($10,016,094), C2N Diagnostics ($7,025,121) and Pharmatrophix ($5,609,700), according to its 2024 IRS Form 990. Together they received 41% of its itemized 2024 grant dollars.

How large is Alzheimer's Drug Discovery Foundation?

Alzheimer's Drug Discovery Foundation reported $299.4M in total assets on its 2024 IRS Form 990. Its revenue that year was $47.3M.

What does Alzheimer's Drug Discovery Foundation fund?

ADDF’s stated mission is to accelerate the discovery of drugs to prevent, treat, and cure Alzheimer’s disease and related dementias. See mission & focus areas ↑

How do I apply for a grant from Alzheimer's Drug Discovery Foundation?

Alzheimer's Drug Discovery Foundation does not accept unsolicited proposals, according to Grantable's research on its published guidelines. Check alzdiscovery.org for any change to that policy.

What is Alzheimer's Drug Discovery Foundation's EIN?

Alzheimer's Drug Discovery Foundation's EIN (Employer Identification Number) is 20-1082179. IRS Form 990 filing data is available on this page for 2019–2024.

Does Alzheimer's Drug Discovery Foundation accept unsolicited proposals?

No, according to Grantable's research on the foundation's published guidelines. See how to apply ↑

Data last updated October 2026. Sourced from IRS Form 990 filings. Research dossier generated October 2026.

Data update history

(7)

When this profile's IRS filing data changed on Grantable

  1. Added Form 990 for fiscal year 2019 (received by the IRS November 16, 2020)
  2. Updated Form 990 for fiscal year 2020 (received by the IRS January 14, 2022)
  3. Updated Form 990 for fiscal year 2021 (received by the IRS November 15, 2022)
  4. Updated Form 990 for fiscal year 2022 (received by the IRS November 15, 2023)
  5. Updated Form 990 for fiscal year 2023 (received by the IRS November 14, 2024)
  6. Updated Form 990 for fiscal year 2024 (received by the IRS November 11, 2025)
  7. IRS filings on file for fiscal years 2020–2024

Other open foundation grants in New York

New York Open opportunities, soonest deadline first.

Explore Open Grants

Browse active grant opportunities in Alzheimer's Drug Discovery Foundation's focus areas in our free grants database

Similar Funders

Funders that support many of the same organizations

Yale University

New Haven, CT

Yale University funds sponsored research, education and institutional programs, student aid, and charitable or community support, with 2025 grants ranging from $3,000 to $14.3 million and a median of about $136,000. Grants went to recipients in multiple states, with the largest shares in Connecticut, California, Massachusetts, New York, and Pennsylvania. The information does not state whether Yale accepts unsolicited requests.

Education

Assets

$58.9B

Grants

364

Total Given

$168.2M

Emory University

Atlanta, GA

Emory University primarily funds research and subcontract work for universities, hospitals, research organizations, and other organizations, across a range of academic and health-related fields. Its 2025 grants ranged from $5,500 to $19.1 million, with a median of about $97,000; 41% of grant dollars went to Georgia recipients. The profile does not state whether Emory accepts unsolicited requests.

Assets

$24.9B

Grants

362

Total Given

$183.7M

President and Fellows of Harvard College

Cambridge, MA

Harvard’s grantmaking primarily supports research and education, including research awards and sub-awards to universities, hospitals, and research institutes. In 2025, it reported 352 grants ranging from $5,002 to $27.4 million, with a median of $123,018; recipients were concentrated in Massachusetts, which received 64% of grant dollars. The profile does not state whether Harvard accepts unsolicited requests.

Assets

$79.9B

Grants

352

Total Given

$273.3M

The Chicago Community Trust

Chicago, IL

The Chicago Community Trust funds eligible nonprofits working to narrow the wealth gap and meet urgent needs, with priorities including economic mobility, education, jobs, homeownership, and community development in metropolitan Chicago and Cook County. Its 2025 grants had a median of $26,500, though amounts varied widely; the profile does not state whether it accepts unsolicited requests.

Assets

$7.1B

Grants

4,316

Total Given

$1.2B

Silicon Valley Community Foundation

Mountain View, CA

Silicon Valley Community Foundation funds work in areas such as housing, economic security, education, health, the environment, arts and culture, and civic engagement, with Community Action Grants supporting local, community-led organizations in San Mateo and Santa Clara counties. Its 2024 grants had a median of $51,716, though amounts varied widely; applications depend on the program, and SVCF states that it does not accept unsolicited proposals for advised funds.

Philanthropy, Voluntarism & Grantmaking

Assets

$12.3B

Grants

3,576

Total Given

$3.2B

IBM International Foundation

Armonk, NY

The IBM International Foundation funds education and workforce programs that build 21st-century and technology job skills, including initiatives for underserved students and job seekers. Its 2024 grants ranged from $10,000 to $8.48 million, with a median of $100,000, and went to organizations across several U.S. states, especially Delaware and Massachusetts. It funds only preselected organizations and does not accept unsolicited requests.

Assets

$357.7M

Grants

16

Total Given

$11.7M

More similar funders

More Funders in New York

Cite this profile

Grantable. (2026). Alzheimer's Drug Discovery Foundation funder profile. GrantGraph. Retrieved October 22, 2026, from https://grantable.co/funders/alzheimer-s-drug-discovery-foundation-morg_ad9e8ac1bfcb49ff96985f74ecaeb1ad

BibTeX
@misc{grantable_201082179_2026,
  author       = {{Grantable}},
  title        = {{Alzheimer's Drug Discovery Foundation funder profile}},
  howpublished = {GrantGraph},
  year         = {2026},
  url          = {https://grantable.co/funders/alzheimer-s-drug-discovery-foundation-morg_ad9e8ac1bfcb49ff96985f74ecaeb1ad},
  note         = {Accessed 2026-10-22. Data licensed CC BY 4.0}
}

The figures on this page are open data under CC BY 4.0: reuse them with credit to Grantable and a link. Download the data.

Figures come from Alzheimer's Drug Discovery Foundation's IRS filings (methodology). AI-written summaries, news items and logos are not covered by the open licence. Spot an error? Email hello@grantable.co.

Alzheimer's Drug Discovery Foundation down — hundreds of funders to go?

Want AI to do this for you?